Floatz logo

Ifosfamide

Hematologic Cancer

Ciusss de L'Est de l'Île de MontréalPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hematologic Cancer cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Indapta Therapeutics, INC.
Phase 4BBB
RANITIDINE
City of Hope Medical Center
Phase 2B
All Trans Retinoic Acid
The First Affiliated Hospital of Soochow University
Phase 2/3B
Elotuzumab
AbbVie (prior sponsor, Abbott)
Phase 2B
Mit-001
MitoImmune Therapeutics
Phase 2CCC
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 1/2CCC
Abbv-101
AbbVie
Phase 1CC

Same molecule, other indications

Ifosfamide is also rated in:

angioimmunoblastic T-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →